PAS-004 Tablets Show Promise for NF1 Plexiform Neurofibromas PAS-004 tablets show dose-proportional, predictable pharmacokinetics with less variability than capsules, supporting improved dosing for NF1-PN.

#PAS004 showed a long half-life of approximately 57 hours, supporting their potential for improved patient dosing and therapeutic consistency in #NeurofibromatosisType1 (NF1)-associated plexiform #Neurofibromas, Pasithea Therapeutics announced.

Read here: https://bit.ly/3KmA4z3

#RareDisease #NF1